Asthma in Children
Conditions
Keywords
soluble receptor for advanced glycation end products, inflammation
Brief summary
sRAGE is a recognized marker of alveolar injury in acute respiratory distress syndrome (ARDS). More recently, it seems to be an interesting marker in asthma. It is the soluble form of the pro-inflammatory RAGE receptor overexpressed in the lungs and in particular the bronchi. It acts as a decoy to its ligands, and thus blocks the pro-inflammatory axis of RAGE. Few studies are available in asthma, especially in children. A local study showed low levels of serum sRAGE in the context of acute bronchiolitis. The same finding emerges from the few studies available in asthma, with rates all the lower when the asthma is poorly controlled. A study carried out in the animal model in 2012 found an absence of inflammatory infiltrate, the absence of increased expression of mucin and the absence of mucus goblet cell hyperplasia within the respiratory epithelium in the absence of RAGE receptor in sensitized mice dust mites, after exposure to their allergen. One could imagine in the long term a potential therapeutic avenue by a substitution in sRAGE in this pathology. The objective of this study is to study the ability of the alveolar sRAGE level measured on broncho-alveolar lavage for assessment, to discriminate the clinical degrees of control of severe asthma in children.
Interventions
DIAGNOSTIC_TESTbronchial endoscopy with bronchoalveolar lavage (LBA)
Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
DIAGNOSTIC_TESTBlood sampling
collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
Sponsors
University Hospital, Clermont-Ferrand
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 16 Years
Healthy volunteers
No
Inclusion criteria
* severe asthma * Weight greater than or equal to 5 kg
Exclusion criteria
* Current respiratory infection * Bronchopulmonary dysplasia or prematurity \< 34 weeks * Diffuse infiltrative pneumonia * Cystic fibrosis, primary ciliary dyskinesia * Known immune deficiencies; * Congenital heart disease; * Cardiomyopathy; * Ongoing pericarditis, myopericarditis, endocarditis; * Chronic valvular pathology; * Known autoimmune disease; * Neuromuscular pathology;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| alveolar sRAGE level | at inclusion | ability of the alveolar sRAGE level measured on bronchoalveolar lavage (BAL) for assessment to discriminate the clinical degrees of control of severe asthma in children |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| plasma sRAGE level | at inclusion | ability of the plasmatic sRAGE level measured on blood for assessment to discriminate the clinical degrees of control of severe asthma in children |
Countries
France
Outcome results
None listed